Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) supporting the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback is a critical milestone for the company as it advances a potential new preventive approach for a disease that affects hundreds of thousands of Americans annually.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons. The study aims to evaluate the prevention of Lyme disease through six months after dosing, with manufacturing of the investigational product on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, potentially providing protection throughout the U.S. Lyme disease season.
Lyme disease is the most common vector-borne illness in the United States, with an estimated 476,000 cases annually. Current preventive measures focus on tick avoidance and early treatment, but no vaccine is available for humans. TNX-4800, if successful, could fill a significant gap in preventive care. The FDA's support for the Phase 2 study design is a positive signal that the development pathway is aligned with regulatory expectations.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) for fibromyalgia marked the first new treatment for the condition in over 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. The company is also evaluating TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, and has TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome.
In the immunology space, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The FDA feedback on TNX-4800 is a key step in the company's strategy to diversify its pipeline beyond CNS disorders.
The news comes as Tonix continues to build momentum following the approval of TONMYA. The company's focus on high unmet medical needs positions it to address significant public health challenges. With the FDA's guidance, Tonix is moving forward with a study that could ultimately provide a new tool in the fight against Lyme disease.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
